SAGE-718
Jump to navigation
Jump to search
Indications
- experimental agent for treatment of Alzheimer's disease, Huntington's disease & Parkinson's disease
Mechanism of action
- positive modulator of NMDA receptors
Clinical trials
- within 2 weeks, improvements in executvie function, learning & memory in patients with Alzheimer's disease
- within 4 weeks, improvement in Montreal Cognitive Assessment scores (+2.3)
More general terms
References
- ↑ Whitlock Burton K Experimental Drug May Boost Executive Function in Alzheimer's Medscape. March 31, 2022 https://www.medscape.com/viewarticle/971365